ライフサイエンスコーパス: abnormal glucose tolerance

1 and subcutaneous fat deposition and markedly abnormal glucose tolerance.

2 Nine of 23 subjects with cystic fibrosis had abnormal glucose tolerance (39%; P = 0.03).

3 for both type 2 diabetes (9.7, 4.3-22.0) and abnormal glucose tolerance (9.0, 4.2-19.7).

4 Abnormal-glucose tolerance (Abnl-GT) is due to an imbala

5 ired insulin and incretin secretion underlie abnormal glucose tolerance (AGT) in pancreatic insuffici

6 e as normal glucose tolerance (NGT, 61.68%), abnormal glucose tolerance (AGT, 26.02%), or DM (13.30%)

7 Abnormal glucose tolerance (AGT; diabetes or impaired gl

8 The CF subjects with abnormal glucose tolerance also had de novo lipogenesis.

9 12 clinically stable adult CF patients with abnormal glucose tolerance and 12 age-, sex-, and lean b

10 y was designed to quantify the prevalence of abnormal glucose tolerance and insulin resistance in pat

11 We show that the Fem1b-KO mice display abnormal glucose tolerance and that this is due predomin

12 Insulin resistance and abnormal glucose tolerance are more prevalent in patient

13 Among participants with abnormal glucose tolerance at baseline, 37.7% (95% CI, 2

14 All differences in prevalence of abnormal glucose tolerance between ADA and WHO classific

15 accompanies this early damage, during which abnormal glucose tolerance can be observed in toddlers.

16 t atrial (LA) measures within the normal and abnormal glucose tolerance categories (the latter includ

17 l diabetes were slightly more likely to have abnormal glucose tolerance compared with those with pate

18 Rs (95% CI) for offspring type 2 diabetes or abnormal glucose tolerance (fasting plasma glucose > or

19 d across HOMA-IR quartiles in the normal and abnormal glucose tolerance groups in both sexes.

20 s disease (PD) and Type 2 Diabetes (T2D), as abnormal glucose tolerance has been reported in >50% of

21 We aimed to compare the prevalence of abnormal glucose tolerance identified by the 1985 WHO an

22 a cell-specific ARNT knockout mice exhibited abnormal glucose tolerance, impaired insulin secretion,

23 t risk for a mild slowly progressive form of abnormal glucose tolerance in addition to overt diabetes

24 sistance contribute to the high incidence of abnormal glucose tolerance in CF.

25 n men and may contribute to the high risk of abnormal glucose tolerance in this population.

26 Although abnormal glucose tolerance is a well-established risk fa

27 In cystic fibrosis, abnormal glucose tolerance is associated with decreased

28 Abnormal glucose tolerance is notably prevalent among yo

29 Translational evidence indicates that abnormal glucose tolerance may begin in early life.

30 In subjects with normal (n=2022) and abnormal glucose tolerance (n=327), covariate-adjusted L

31 insulin secretion is impaired in people with abnormal glucose tolerance, nonglucose nutrient-induced

32 tudy: six male/six female; seven normal/five abnormal glucose tolerance (oral glucose tolerance test

33 Glucose tolerance normalized in one abnormal glucose tolerance subject.

34 tures (RP with blindness by age 13, BMI >45, abnormal glucose tolerance test and IQ=64, vaginal atres

35 Metabolism investigations showed abnormal glucose tolerance tests and low HDL values in s

36 actors and, among at-risk women, testing for abnormal glucose tolerance that is usually, but not inva

37 fat accrual and a threefold higher risk for abnormal glucose tolerance, while individuals with hyper